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ABSTRACT 26 
 27 
Endophytic bacteria, such as Streptomyces, have the potential to act as a source for novel 28 
bioactive molecules with medicinal properties. The present study was aimed at assessing the 29 
antimalarial activity of crude extract isolated from various strains of actinobacteria living 30 
endophytically in some Malaysian medicinal plants. Using the four day suppression test 31 
method on male ICR strain mice, compounds produced from three strains of Streptomyces 32 
(SUK8, SUK10 and SUK27) were tested in vivo against Plasmodium berghei PZZ1/100 in an 33 
antimalarial screen using crude extracts at four different concentrations. One of these 34 
extracts, isolated from Streptomyces SUK10 obtained from the bark of Shorea ovalis tree, 35 
showed inhibition of the test organism and was further tested against P. berghei-infected 36 
mice for antimalarial activity at different concentrations. There was a positive relationship 37 
between the survival of the infected mouse group treated with 50 µg kg-1 body weight (bw) of 38 
ethyl acetate-SUK10 crude extract and the ability to inhibit the parasites growth. The parasite 39 
inhibition percentage for this group showed that 50% of the mice survived for more than 90 40 
days after infection with the parasite. The nucleotide sequence and phylogenetic tree 41 
suggested that Streptomyces SUK10 may constitute a new species within the Streptomyces 42 
genus. As part of the drug discovery process, these promising finding may contribute to the 43 
medicinal and pharmaceutical field for malarial treatment. 44 
 45 
INTRODUCTION 46 
 47 
Climate change and population movement are among the factors that have contributed to an 48 
increase in disease (Pillay and Zambon, 1998; Espinel et al., 2001). Malaria is the most 49 
VLJQLILFDQW KXPDQ SDUDVLWLF GLVHDVH WKDW LQFUHDVLQJO\ WKUHDWHQV PDQ\ RI WKH ZRUOG¶V50 
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population, particularly children and the elderly due to the emergence of drug resistance (Joy 51 
et al., 2003; Bray et al., 2005; Yotoko and Elisei, 2006). Chloroquine resistance is common 52 
in Malaysia and most parts of South East Asia (Wellems, 2002; Abdulelah and Zainal-53 
Abidin, 2007) and there is also clinical and laboratory evidence of resistance to sulfadoxine 54 
or pyrimethamine in combination as well as quinine (Wellems, 2002). 55 
Tropical forests in Malaysia are among the oldest on the planet and as many as 1,300 56 
plants from this environment are claimed to have medicinal properties. However, most of 57 
them have not been scientifically studied (Ibrahim et al., 1994). Previous findings have 58 
showed that the plants used by the native population in Malaysia as alternative medicines 59 
provide a habitat for endophytic microorganisms (Behal 2000; Strobel and Daisy, 2003; Zin 60 
et al., 2011) and may have potential to treat malaria. Actinomycetes in general, and 61 
streptomycetes in particular, produce over two-thirds of clinically useful antibiotics of natural 62 
origin (Kurosawa et al., 2000; Berdy 2005; Fiedler et al., 2005). These Gram positive 63 
bacteria with high G-C content, complex morphological (Flärdh and Buttner, 2009) and 64 
physiological differentiation (Bibb 2005). Various reports showed that endophytic members 65 
of the genus Streptomyces have the ability to inhibit a variety of human pathogens, including 66 
bacteria and fungi (Rajendra et al., 2004; Ghadin et al., 2008; Zin et al., 2010;  Zin et al,. 67 
2011). For example, the endophytic strain Streptomyces NRRL 30562 from Kennedia 68 
nigriscans produces at least one broad spectrum antibiotic (Coombs and Franco, 2003). 69 
In this study, three endophytic Streptomyces isolates named SUK8, SUK10 and SUK27 70 
were obtained from the Malaysian plants Scindapsus hederaceus, Shorea ovalis and Zingiber 71 
spectabile, respectively. The aim of the present study is to assess the in vivo antimalarial 72 
activity against Plasmodium berghei PZZ1/100 strain by administrating crude extracts of 73 
cultures of each endophytic bacterium.  74 
 75 
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MATERIALS AND METHODS  76 
 77 
Plant selection and sterilization technique  78 
 79 
Plant voucher number, HM449820 for S. hederaceus, HM449822 (S. ovalis) and GU238266 80 
(Z. spectabile) were submitted to the Universiti Kebangsaan Malaysia (UKM) Herbarium 81 
Unit to obtain a tagging code. The sterilization and isolation of the bacteria from the plants 82 
were modified from Coombs and Franco (2003). Briefly, the plants were dried at room 83 
temperature for 48 hours before being thoroughly washed with tap water. Internal bark of S. 84 
hederaceus and S. ovalis and the external stem of Z. spectabile were cut into 5.0 cm long 85 
strips and washed with sterile water to remove soil particles and epiphytic microorganisms. 86 
The selected part of the plants were then excised and subjected to a three-step procedure of 87 
surface sterilization: one minute wash in 99 % (v/v) ethanol, followed by a six minute wash 88 
in 3.5 % NaClO (v/v) and a final three-times rinse with sterilized distilled water (sdH2O). The 89 
effectiveness of surface sterilization procedure was tested by plating 1.0 ml of the final rinsed 90 
sdH2O on to nutrient agar. After 37°C incubation for seven days, the sterilization procedure 91 
was assumed to be successful if there were no microbial growth on the agar. 92 
 93 
Isolation and identification of the bacteria 94 
 95 
The outer most skin of all sterilized bark and stem of the plants were cut out. These parts 96 
were then aseptically cut as cross-sections into two to three mm thin slices to allow the outer-97 
most, middle and inner-most parts of the samples to be placed on three different agars: 98 
actinomycete Isolation Agar (AIA), Starch Yeast Casein Agar (SYCA) and Water Agar 99 
(WA) (Castillo et al., 2002). All agars were supplemented with 5.0 ml of 50 µg mL-1 100 
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cycloheximide and 50 µg ml-1 nystatin as antifungal agents. Bacterial growth on the agar was 101 
assessed after four weeks incubation at room temperature (RT) and identified as 102 
streptomycetes on the basis of their colony morphology and colour before they were 103 
subcultured onto International Streptomyces Project 2 (ISP2) agar for the next phase of study. 104 
The endophytic Streptomyces colonies were then macroscopically checked using 105 
normal light microscope under 40× magnification. Aerial and substrate mycelium colour, 106 
dissolved pigment colour and spore chain morphology were among the macroscopic 107 
characteristics observed. Gram staining was also done to permit the visualisation of the 108 
RUJDQLVP¶V PLFURPRUSKRORJ\ $OO RI WKH LVRODWHV WKDW GLVSOD\HG WKH PRUSKRORJLFDO109 
characteristics of Streptomyces ZHUHWKHQJLYHQWKHLU8.0¶VGHSRVLWLRQQXPEHUEHIRUHWKH\110 
were kept as pure stock culture at -80°C by adding five pieces of (5 × 5) mm thin slices of 111 
isolate mycelium to 1.0 ml of glycerol 80% (v/v) (Castillo et al., 2002).   112 
 113 
Production of crude extract 114 
 115 
Nutrient broth (Sigma-Aldrich, Malaysia) was prepared at different pH levels: 6.5, 7.0 and 116 
7.5. To produce extracts of the isolates, five blocks of 5 × 5 mm ISP2 agar enriched with 117 
Streptomyces were cut and inoculated into 400 ml autoclaved nutrient broth in a 1000 ml 118 
conical flask individually. Fermentations were carried out using an orbital shaker at 28oC at 119 
three different rotation rates; 180, 200 and 220 RPM for 19 ± 21 days. The supernatant was 120 
then extracted three times using the selected solvents at a ratio of 1:2 of pool supernatant. 121 
Prior to this, 1200 mL of supernatant were extracted with 200 mL of ethyl acetate three times 122 
(Castillo et al., 2002).  123 
 124 
In vivo antimalarial screening 125 
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 126 
All animal experiments were conducted following approval by the UKM Animal Ethics 127 
Committee (UKMAEC) coded FSK/Biomed/341. Using ICR strain male mice at 28 ± 30 g 128 
body weight (bw) and aged six weeks old as the model, the parasite Plasmodium berghei 129 
PZZ1/100 was administered into the host via the intraperitoneal (IP) route. Every group of 130 
mice (n = 6) was housed in a  stainless steel cage, treated at room temperature with daily ad-131 
libitum feeds at 12-12 hours both with and without a light period. In order to assess the 132 
extract activity, the four days (4D) suppression test method (Abdulelah and Zainal-Abidin, 133 
2007) was applied. For the treatment, ethyl acetate-SUK8, -SUK10 and -SUK27 crude 134 
extracts were diluted with 1:10 (DMSO:dH2O).  As demonstrated by previous studies (Ata-135 
ur-Rehman et al., 1985, Peters and Robinson, 1992, Anthony et al., 2005, Abdulelah and 136 
Zainal-Abidin, 2007),  no physical side effects observed on the treated host with 10% of 137 
DMSO. For the positive and negative controls, 10 mg kg-1 bw of dH2O diluted quinine 138 
hydrochloride and 0.9% normal saline respectively were used (Peters and Robinson 1992, 139 
Abdulelah and Zainal-Abidin, 2007).   140 
Infected blood collected IURPWKHWLSRIWKHGRQRUPLFH¶VWDLOZDVVHULDOO\GLOXWHGZLWK141 
$OVHYHU¶VVROXWLRQWRREWDLQ[6 parasitized red blood cells (RBC) before they were IP 142 
administered at 0.1 mL to all the tested mice (Abdulelah and Zainal-Abidin, 2007). Within 143 
two hours, these mice were immediately treated with 0.1 mL of ethyl acetate-crude extract 144 
and also 0.1 mL of both positive and negative control solutions. This point was considered as 145 
day zero (D0). Without repeating the parasite infection, the same treatment was repeated for 146 
the next three days and referred to as D1, D2 and D3. On D4, a blood smear from the treated 147 
mice was stained with Giemsa to obtain parasitemia density (%) and parasitemia inhibition 148 
(%). The mice were also observed daily for survival time (day) calculated after 20 days post-149 
infection. Considering that the treatment used in this study was a crude extract and, as 150 
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documented in previous studies, (Ata-ur-Rehman et al., 1985, Anthony et al., 2005, 151 
Abdulelah and Zainal-Abidin, 2007), results with a parasitemia inhibition of > 65% were 152 
considered as having antimalarial activity and the mouse group with the longest survival time 153 
considered as receiving the best treatment. The value for parasitemia density directly reflects 154 
the value of inhibition percentage, where the higher the inhibition percentage, the better the 155 
treatment effect was (Abdulelah and Zainal-Abidin, 2007), where;  156 
 157 
Inhibition (%)  =  Parasitemia of negative control ± Parasitemia of treatment   ×  100 158 
                                                   Parasitemia of negative control 159 
 160 
Treatment for tested and control groups by in vivo screening underwent the same 161 
procedures with five different narrower concentrations of the extracts; 5, 10, 50, 100 and 200 162 
µg kg-1 bw which was implemented only for the best crude extract isolate performed in 163 
preliminary screening. Similarly, the best among these five concentrations was determined 164 
when the parasitemia inhibition was > 65% in conjunction with the mouse group that showed 165 
the best survival. 166 
 167 
DNA extraction of endophytic Streptomyces isolates 168 
 169 
The genomic DNA was isolated by neutral lysis, followed by phenol-chloroform extraction 170 
and precipitation with isopropanol. The DNA from the isolates was extracted using a 171 
modified protocol (Keiser et al., 2000) where 30 ± 50 mg of Streptomyces mycelium was 172 
suspended with 500 µL lysozyme buffer in a 1.5 mL Eppendorf tube by vortexing before 25 173 
µL of 50 mg mL-1 lysozyme and 3.0 µL of 10 mg mL-1 RNase were added and the sample 174 
vortexed for 10 seconds. At the end of the extraction process, a Thermo Scientific Nano-Drop 175 
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2000C machine was then used to determine the purity and concentration reading for the 176 
isolated DNA. 177 
 178 
Amplification and sequencing of the 23S rDNA gene 179 
 180 
Polymerase Chain Reaction (PCR) was performed using the 23S rDNA gene primer pair  181 
(P1-¶$&&$**$7*&77$*$$*¶ FRUUHVSRQGLQJ WR E. coli 1051 ± 1071 nucleotide 182 
sequence of 23S rDNA gene and also P2-¶&$&77$&&&&*$&$$**$$7¶183 
corresponding to E. coli 1957 ± 1938 nucleotide sequence of 23S rDNA gene). PCRs were 184 
carried out in 50 µL reactions containing 10 µL MyTaq buffer (5× PCR buffer contained 10 185 
mM dNTPs and 25 mM MgCl2), 1.0 µL of both 20 mM reverse and forward primer, 2.0 µL 186 
of 5 U/uL MyTaq polymerase enzyme. Then 2.0 µL of 60.5 ng/µL DNA template and 34 µL 187 
deionized H2O. The PCR thermocycling conditions were as follows: initial denaturation of 188 
DNA template at 95°C for two minutes; followed by 30 cycles of denaturation at 95°C for 30 189 
seconds, primer annealing at 54°C for 30 seconds, extension at 72°C for 60 seconds and a 190 
final extension at 72°C for five minutes. The resulting PCR products were purified by using 191 
the Wizard PCR Prep DNA purification kit (Promega UK) before being sent for sequencing 192 
at Eurofins UK using primers P1 and P2. The 23S rDNA sequences obtained were then 193 
compared to the Genbank databases by using basic local alignment search tool (BLAST).  194 
 195 
Identification of compounds 196 
 197 
With hexane and ethyl acetate as the mobile phase A and B respectively, 2.8 g of selected 198 
isolate crude extract was fractionated (GRACE Biotage Flash Chromatography). The extract 199 
was chromatographed over 40 g generic silica while the columns were detected under 245 200 
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and 310 nm of respective UV1 and UV2 absorptions wavelength and coupled with 201 
isopropanol as electron light scattering detector (ELSD) at 5.0 mV. The elution was done at 202 
35 mL/min for 80.0 minutes run length. The thin layer chromatography (TLC) analysis was 203 
done on all 22 fractions by dissolving the sample with appropriate solvents and was 204 
visualized using the UV light with short and long wavelengths of 254 nm and 350 nm 205 
respectively. These fractions were selected in order to determine the optimized solvent 206 
system that lead to the visualization of the compounds observed in TLC. All of the samples 207 
obtained during the fractionation process were dissolved in denatured chloroform (CDCl3) 208 
and tested by NMR for determination of its chemical structure and configuration. This 209 
method was implemented using NMR AS400 for 400 MHz and Bruker FT-NMR for 600 210 
MHz. The fractions that underwent NMR experiments were subjected for 1D and 2D 1H 211 
analysis. COSY (400 Mz), HMBC (6 hours) and HMQC (8 hours) were also further 212 
implemented for interesting fractions with promising characteristics (fractions 11, 15 and 20), 213 
as well as for 13C and DEPT (both 4 hours) individually. In addition to the NMR profiles, 214 
high resonance liquid chromatography mass spectrometry (HR-LCMS) analysis (ACCELA 215 
Auto-Sampler, UK) was also carried out and the data were then compared with the 216 
information documented in AntiBase library to obtain any supportive data for determination 217 
of the compound identity. 218 
 219 
Statistical analysis 220 
 221 
All results were expressed as the mean ± standard deviation (sd) from six mice per group. 222 
Due to the small sample size for each treated group of mice (n = 6), the Shapiro-Wilk test 223 
was used to analyse the significance of the antimalarial tests. Statistical significance was 224 
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declared when P value was equal to or less than 0.05 (3  ). Since all groups were 225 
normally distributed, no non-parametric tests were required in this study. 226 
 227 
RESULTS 228 
 229 
Identification of the bacterial strains 230 
 231 
Micro- and macro-morphology differences between all three strains were used as a 232 
preliminary means to identify the isolates as members of the genus Streptomyces. The 233 
relation between names, part of the plants, 8.0¶V WDJJHG voucher number, the aerial and 234 
substrate mycelium colour, dissolved pigment colour and spore chain morphology, as well as 235 
Gram staining colour for all of the tested strains are shown in Table 1. Other than living 236 
endophytically in the same part of their respective plants, SUK8 and SUK10 also showed 237 
similarities in most of macroscopic and microscopic observations, except for their substrate 238 
mycelium colour.  239 
 240 
Production of crude extract 241 
 242 
After culture optimization, all strains produced most biomass after 21 days fermentation in 243 
nutrient broth at pH 7.0 and at an agitation rate of 200 RPM. Extract yields of more than 40 244 
mg were only obtained from all strains with an agitation rate of 200 RPM and nutrient broth 245 
at pH 7.0. Consequently these conditions were used for 21 days to isolate SUK10 crude 246 
extracts with ethyl acetate for implementing in vivo antimalarial screening. 247 
To produce large amounts of crude extract, a scaled-up fermentation with SUK10, the 248 
strain that exhibited the strongest activity against P. berghei PZZ1/100 was then carried out 249 
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using the best variant of pH, aeration rate and optimized length of fermentation. These 250 
conditions were characterized based on the highest amount of crude extract produced. This 251 
process was repeated in a 1000 mL conical flask using the orbital shaker until the crude 252 
extract reached sufficient weight which at least 25.0 mg for in vivo antimalarial screening. At 253 
the end of the fermentation period, this culture was filtered to separate the mycelium from its 254 
supernatant and extracted using ethyl acetate three times before the organic solvent phase was 255 
pooled prior to a drying process using a rotary evaporator. 256 
 257 
In-vivo antimalarial screening of tested isolates 258 
 259 
In order to determine the isolate that exhibited the best antimalarial activities we used three 260 
main parameters; parasitemia density, inhibition rate and survival time. For parasitemia 261 
density, the SUK10 crude extract at all concentrations (50, 100, 200 and 400 µg kg-1 bw) 262 
exhibited the lowest value compared with SUK8 and SUK27 (Table 2). With the lowest 263 
parasitemia density at 1.08 ± 0.9%, there was a significant difference for this parameter (P < 264 
0.05, n = 6) at 100 µg kg-1 bw between SUK10 and the other two isolates. The same results 265 
were also observed for the other three concentrations levels. Meanwhile at 400 µg kg-1 bw, 266 
2.64 ± 3.7% was recorded as the highest value of parasitemia density of SUK10; however 267 
this was still lower compared with SUK8 (2.98 ± 6.1%) and SUK27 (4.04 ± 5.3%).  268 
For the inhibition rate shown in (Fig. 1A), at all concentrations the SUK10 crude 269 
extract exhibited the highest percentage compared with SUK8 and SUK27. With the highest 270 
inhibition rate 84.14 ± 2.6% at 100 µg kg-1 bw, there was a significant difference (P < 0.05, n 271 
= 6) between SUK10 and the other two isolates at this concentration. As the inhibition rate at 272 
more than 65% was considered as a benchmark of in vivo antimalarial activity (Ata-ur-273 
Rehman et al., 1985, Abdulelah and Zainal-Abidin, 2007), all the percentages observed for 274 
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SUK10 were higher than 70%, except 51.44 ± 0.9 % at 400 µg kg-1 bw. No inhibition rates 275 
higher than 65% were observed for the other two isolates at all concentrations except 71.14 ± 276 
1.2% at 50 µg kg-1 bw and 67.45 ± 3.4% at 200µg kg-1 bw, both exhibited by SUK8 isolate.  277 
Despite this, these values were still lower than those observed from the crude extract of 278 
SUK10 isolate at the same concentrations. 279 
It was predicted that survival times of the treated mice would be longer at higher 280 
inhibition rates. Mice groups treated with the SUK10 crude extract at all concentrations 281 
exhibited the longest survival time compared with the other isolates at the same 282 
concentration. In accordance with the inhibition rate, the mouse group treated with SUK10 283 
crude extract at 100 µg kg-1 bw managed to survive up to 21 days post-infection as well as 18 284 
and 16 days for the other concentrations (Fig. 1B). There was also a significant difference for 285 
the mice survival time (P < 0.05, n = 6) at 100 µg kg-1 bw between SUK10 and the other two 286 
strains. 287 
 288 
In-vivo antimalarial screening of SUK10 289 
 290 
The SUK10 extract was subjected to final in vivo antimalarial screening with five different 291 
concentrations across a narrower range (5, 10, 50, 100 and 200 µg kg-1 bw) in order to 292 
determine which concentration gives the best in vivo antimalarial activity. With only 1.64 ± 293 
3.0% at 100 µg kg-1 bw, there was a significant difference for parasitemia density (P < 0.05, n 294 
= 6) between 100 µg kg-1 bw and the other four concentrations. Nevertheless, 1.86 ± 3.1% 295 
observed for 50 µg kg-1 bw was still lower compared to the other concentrations (Table 3). 296 
The blood slides taken on D4 for every concentration of SUK10 treatments from particular 297 
mice showed that the distribution of four main stages of P. berghei lifecycle were 298 
successfully captured in the infected-RBC (Fig. 2). This figure indicated that the complete 299 
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GHYHORSPHQW RI RQH SODVPRGLDO¶V OLIHF\FOH LQ suppressed vertebrate host was completed 300 
within four days after infection.    301 
Since every concentration had its own negative control group individually, the 302 
inhibition rate for 50 µg kg-1 bw was relatively high and gave the greatest value, although the 303 
parasitemia density was quite lower at 100 µg kg-1 bw compared with 50 µg kg-1 bw (Fig. 304 
3A). The concentration at these two values, together with the concentration at 200 µg kg-1 305 
bw, were considered as the concentrations where antimalarial activity could be best assessed 306 
because the value obtained at 5 µg kg-1 bw and 10 µg kg-1 bw was lower than 65% (Ata-ur-307 
Rehman et al., 2005, Abdulelah and Zainal-Abidin, 2007). At the highest value, 70.89 ± 308 
3.1%, there was a significant difference (P < 0.05, n = 6) between 50 µg kg-1 bw and the 309 
other four concentrations.  310 
In this study, the longest survival time observed was 91.11 ± 0.5 days post-infection 311 
(data not shown), which was exhibited by half of the total mice (n = 3) treated with 50 µg kg-312 
1
 bw ethyl acetate-SUK10 crude extract. Surprisingly, the remaining half  of these mice (n = 313 
3) in this group also managed to survive between 55 ± 65 days post-infection which was far 314 
longer than the other four groups for SUK10 at this phase (Fig. 3B).  315 
 316 
Preliminary identification of SUK10 by 23S rDNA sequencing 317 
 318 
Since SUK10 showed the most significant antimalarial activity, the amplification of 23S 319 
rDNA gene was only done on this strain. SUK10 samples generated an amplicon close to the 320 
predicted size of 1Kb (data not shown). After sequencing, this product was confirmed to be 321 
1006 bp in length with the score 97% of multiple sequence alignments. The BLASTN results 322 
of two independent SUK10 sequences revealed that the nucleotide sequence has 94% - 96% 323 
identity with other species, with Streptomyces hygroscopicus jinggangensis having the 324 
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highest homology. The neighbour joining phylogenetic tree (Fig. 4) suggested that 325 
Streptomyces SUK10 may constitute a new species within the Streptomyces genus. Due to 326 
this promising outcome, detailed characterization of SUK10 strain is currently being done in 327 
our laboratory to determine the full genome sequence of this strain.  328 
 329 
Identification of compounds 330 
 331 
Twenty-two fractions (V1 ± V22) were obtained following separation of spots by TLC 332 
(fraction 1 ± 7 under development in 80:20 (v/v) of hexane/ethyl acetate, fraction 8 ± 13 333 
(60:40, v/v, hexane/ethyl acetate) and fraction 14 ± 22 (90:10, v/v, DCM/methanol).  The 334 
obtained yield and the compound identity name from all fractions of SUK10 crude extract are 335 
shown in Table 4. Due to the interesting peak displayed by fraction 15, this fraction was also 336 
subjected for 13C and DEPT (600 Mz, 4 hours). The pure fraction in vial number 15 (V15) 337 
was revealed as a type of prolyl-leucyl-diketopiperazine namely Gancidin W (Bin et al., 338 
2009) based on 1D 1H-13C and 2D 1H-1H NMR analysis, COSY, HMBC, HMQC and DEPT 339 
tests of NMR correlation data and Antibase Library data.  16.2 mg of this compound was 340 
isolated as a light brownish solid with molecular formula (MF) C11H18N2O2 and molecular 341 
weight (MW) 210.275 at retention time 7.17 minutes. The assignment of the 1H and 13C 342 
NMR signal of Gancidin W are shown in Table 5.  343 
 344 
DISCUSSION 345 
 346 
While the efficacy of the extracts of SUK8 and SUK27 were comparable for all parameters in 347 
this study, some of the parameters observed for SUK8 such as parasitemia density at 400 µg 348 
kg-1 bw and inhibition rate and survival time at 50 µg kg-1 bw were approximately the same 349 
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value as obtained for SUK10. It was noted that, for all parameters obtained in the final 350 
antimalarial screening for SUK10, survival time for the mouse group treated with 100 µg kg-1 351 
bw was similar to those treated with 200 µg kg-1 bw. The reasons behind this may be 352 
multifactorial. Aside from the fact that the progression of the erythrocytic cell cycle in 353 
Plasmodium-infected host is poorly understood (Prudhomme et al., 2008), every secondary 354 
metabolite classes contained in the crude extracts has their own characteristics such as active 355 
groups and polarity indexes (Zin et al., 2011) and also, there may be a tendency to obtain 356 
more significant values for those parameters in particular cycles or stages of the Plasmodium 357 
life cycle. These factors were not considered in this study.  358 
Clinically, it is more practical to give the daily treatment with antimalarial drugs 359 
containing particular active functional groups for more than seven days (Rajendra et al., 360 
2004; Abdulelah and Zainal-Abidin, 2007), depending on the treatment regime combination, 361 
stage of infection and type of plasmodial species (Ernest, 1995; Foley and Tilley, 1998; 362 
Kurosawa et al., 2000; Rajendra et al., 2004; Abdulelah and Zainal-Abidin, 2007). At the 363 
present time, the chemical structure and active functional groups in all tested crude extracts 364 
that are responsible for antimalarial activity has not yet been determined to a high level of 365 
detail. 366 
Considering all concentrations both in preliminary antimalarial screening and  367 
antimalarial screening of SUK10 extracts, all the untreated control mice died between seven 368 
and nine days post infection and more than 18 months post infection for positive control. This 369 
was also described in previous in vivo antimalarial studies (Zainal-Abidin et al., 1985; 370 
Kurosawa et al., 2000; Isaka et al., 2002; Jochen et al., 2002; Abdulelah and Zainal-Abidin, 371 
2007; Prudhomme et al., 2008). 372 
In agreement with the in vitro data as well as that observed in other studies (Kurosawa 373 
et al., 2000; Isaka et al., 2002; Abdulelah and Zainal-Abidin, 2007; Prudhomme et al., 2008), 374 
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it is possible that survival time of the treated mice might be longer at the higher inhibition 375 
rate value, which was also observed in this study. Several previous studies (Zainal-Abidin et 376 
al., 1985; Kurosawa et al., 2000; Jochen et al., 2002; Rajendra et al., 2004, Abdulelah and 377 
Zainal-Abidin, 2007; Prudhomme et al., 2008) found that 50 ± 150 µg kg-1 bw is the best 378 
range of dose for the treatment of crude extract in order to fulfil the same parameters. This 379 
may explain why in this study, the parasitemia density rose up at 200 µg kg-1 bw (Table 3) 380 
before stabilizing at 100 µg kg-1 bw in antimalarial screening for SUK10 strain and the 381 
inhibition rate decreased at the same concentration (Fig. 3A). To support these findings, some 382 
previous studies documented that SUK10 also exhibited very strong antimicrobial activity 383 
against Bacillus subtilis ATCC 6633 at inhibition percentage 76.2% and B. cereus ATCC 384 
6464 (76.4%) as well as antifungal activity against Aspergillus fumigatus (84.6%), 385 
Rhizoctonia solani (94.1%) Geotrichum candidum (91.7%), Trichoderma viridae and 386 
Fusarium solani (both 100%) (Ghadin et al., 2008, Zin et al., 2010). 387 
Based on the 1H NMR analyses in this study, fraction V15 was found to contain 388 
interesting signals that corresponded to the major constituent. V15 at 98% purity was isolated 389 
at 16.2 mg (0.31% yield) as light brownish solid material with a molecular weight 210.275 390 
and molecular formula of C11H18N2O2 established by HR-LCMS at a retention time of 7.17 391 
minutes. In this paper, the nomenclature Gancidin W (GW) was assigned for the isolated 392 
compound V15. The peak displayed in fraction was determined to be GW. This is a natural 393 
compound of the alkaloid group (Adamczeski et al., 1995; Bin et al., 2009) and as such this 394 
compound is suspected to be responsible for antimalarial activity shown in this study. Natural 395 
compounds in the alkaloid group are among the most investigated compounds in terms of 396 
antimalarial research (Fernandez et al. (2009). For instance, by using the 4D suppressive test 397 
on the mice, Cassiarin A that was isolated from the leaves of Cassia siamea (Leguminosae) 398 
showed an inhibitory effects against P. falciparum with IC50 value of 0.02 ȝ0(NDVDULet al. 399 
17 
 
2009). Other than that, alkaloid components isolated from the Bhutanese medicinal plant 400 
Corydalis calliantha (Fumariaceae) were used for the treatment of malaria in Bhutan. 401 
Protopine and Cheilanthifoline showed promising in vitro antimalarial activities against P. 402 
falciparum (both wild type (TM4) and multidrug-resistant (K1) strains, with IC50 values of 403 
2.78 ±  ȝ0) (Wangchuk et al. 2010). The 1H and 13C data for V15 (Table 5) were in 404 
accordance to the cyclodipeptide structure for S-prolyl-R-leucyl-diketopiperazine, previously 405 
isolated from the sponges Calyx cf. podatypa (Adamczeski et al., 1995) and Callyspongia 406 
(Bin et al., 2009). A similar compound, named as Gancidin W and elucidated as cyclo-(L-407 
leu-L-pro) but with unknown absolute stereochemistry, was earlier isolated from strains of 408 
Streptomyces gancidus (Jain et al., 1977). In this study, the natural product gave an optical 409 
rotation of [D]D ±138.2 (c = 1.0, EtOH) which was compatible with those isolated earlier 410 
from other Streptomyces strains (Jain et al., 1977). This diketopiperazine (DKP) derivative 411 
compound is naturally produced by many organisms and displays a wide diversity of 412 
structures and biological functions (Smaoui et al., 2012). This scenario suggests that 413 
Gancidin W may be a useful chemical entity for the discovery and development of new 414 
drugs. Some DKP derivatives have already been demonstrated to have a good biological 415 
activity such as antibacterial, antiviral, antitumor, fungicidal and many more (Belin et al., 416 
2012; Magyar et al., 1999). Although Gancidin W was previously identified in extracts from 417 
other Streptomyces sp. (Ben Ameur Mehdi et al., 2004; Rhee, 2002), its antimalarial 418 
properties have not yet been reported.  419 
Consequently through the significance level of statistical tests, the consistency of the 420 
values for malarial inhibition in this study are promising and the results reported in this paper 421 
indicate that Streptomyces SUK10 has good potential as producing an antimalarial agent.  422 
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Table 1. The respective relationship between plants, its tagged voucher number, macroscopic 568 
and microscopic observation of all strains.  569 
 570 
Strain Plant Plant part Voucher 
number 
Aerial 
mycelium 
colour 
Substrate 
mycelium      
colour 
Dissolved 
pigment 
colour 
Spore       
chain 
morphology 
Gram 
stain 
colour 
SUK8 Scindapsus 
hederaceus 
Bark 
(internal) 
HM449820 Whitish 
grey 
Light 
brownish 
Yellow Spiral Purple 
SUK10 Shorea 
ovalis 
Bark 
(internal) 
HM449822 Whitish 
grey 
Brownish 
yellow 
Yellow Spiral Purple 
SUK27 Zingiber 
spectabile 
Stem 
(external) 
GU238266 White Brownish 
yellow 
Yellow Rectus Purple 
 571 
 572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
 582 
 583 
 584 
 585 
 586 
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Table 2. Parasitemia density (%) on day-4 (D4) for treatment and control groups at four 587 
different concentrations in preliminary antimalarial screening 588 
 589 
Group Description Parasitemia density (%) 50# 100# 200#  400#  
Control Positive Negative 
0.00 ± 0.0* 
5.03 ± 2.1* 
0.00 ± 0.0* 
6.82 ± 1.6* 
0.00 ± 0.0* 
5.17 ± 3.0* 
0.00 ± 0.0* 
5.44 ± 2.4* 
Treatment 
SUK8 
SUK10 
SUK27 
1.45 ± 0.7* 
1.32 ± 1.5* 
3.11 ± 0.8* 
2.35 ± 4.0* 
1.08 ± 0.9*§ 
2.23 ± 1.0* 
2.22 ± 0.1* 
1.11 ± 2.7*§ 
3.33 ± 0.3* 
2.98 ± 3.1* 
2.64 ± 3.7* 
4.04 ± 2.3* 
* : Mean ± standard deviation (s.d.)   590 
# : Concentration (µg kg-1) 591 
§ : p < 0.05 592 
 593 
 594 
 595 
 596 
 597 
 598 
 599 
 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
26 
 
Table 3. Parasitemia density (%) on day-4 (D4) for ethyl acetate-SUK10 crude extract 609 
treatment and control groups at five different concentrations in antimalarial screening of 610 
SUK10 isolate. 611 
 612 
Group Parasitemia density (%) 5#  10# 50# 100# 200# 
Positive control 
Negative control 
0.00 ± 0.0* 
5.11 ± 2.1* 
0.00 ± 0.0* 
6.21 ± 1.6* 
0.00 ± 0.0* 
6.39 ± 3.2* 
0.00 ± 0.0* 
5.40 ± 2.4* 
0.00 ± 0.0* 
6.11 ± 0.7* 
Treatment    §  
* : Mean ± standard deviation (s.d.)   613 
# : Concentration (µg kg-1) 614 
§ : p < 0.05 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
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Table 4. The yield obtained from all isolated fractions of SUK10 crude extract and their 631 
compound identity 632 
 633 
Solvent system Fraction Net weight 
(g) 
Compound 
Hexane and 
ethyl acetate 
(H:EA = 8:2) 
V1 0.1106 Long chained triglyceride fatty acid 
V2 0.0271 Long chained triglyceride fatty acid 
V3 0.8132 Long chained triglyceride fatty acid 
V4 0.1255 Long chained triglyceride fatty acid 
V5 0.0890 Long chained triglyceride fatty acid 
V6 0.0393 Macrotetrolide B (C47H72O12) 
V7 0.0162 Swalpamycin B (C36H58O13) 
Hexane and 
ethyl acetate 
(H:EA = 6:4) 
V8 0.0185 Milbemycin A8 (C40H60O10) 
V9 0.0125 Phenalamide C (C32H45NO4) 
V10 0.0301 Eicosanedioic acid (C20H38O4) 
V11 0.0249 3-indole lactic acid (C11H11NO3) 
V12 0.0287 Monacolin L (C19H30O4) 
V13 0.0283 Platensimycin B3 (C23H27NO5) 
Dichloromethane 
and methanol 
(DCM:M = 9:1) 
V14 0.0191 Mollicellin D (C21H21ClO6) 
V15 0.0162 Gancidin W (C11H18N2O2) 
V16 0.0113 Gymnodimine B (C32H45NO5) 
V17 0.0276 Venturicidin A (C40H66O10) 
V18 0.0082 Aspereline F (C46H82N10O1) 
V19 0.0300 Long chained triglyceride fatty acid 
V20 0.0498 Long chained triglyceride fatty acid 
V21 0.0142 Long chained triglyceride fatty acid 
V22 0.0184 Long chained triglyceride fatty acid 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
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Table 5. Assignment of the 1H and 13C NMR signal of GW at 400 MHz in CDCl3.  644 
 645 
Position Gancidin W. (Helvetica Chimica Acta  
Vol. 92) (Bin et al., 2009) 
SUK10  
(Gancidin W) 
įH (J in Hz) įC įH (J in Hz) įC 
1 C - 172.9 - 166.0 
2 - - - - - 
3 CH2 3.54 ± 3.51 (m) 46.5 3.55 (m) 45.8 
4 CH2 1.94 ± 1.87 (m), 2.06 ± 1.99 (m) 23.6 1.88 (m), 2.02 (m) 23.1 
5 CH2 2.35 ± 2.31 (m), 1.96 ± 1.87 (m) 29.1 2.33 (m), 2.03 (m) 29.2 
6 H±C 4.15 (br. s) 60.3 4.08 (d) 59.3 
7 C - 168.9 - 170.0 
8 N±H  - - 6.44 (s) - 
9 H±C  4.29 (t, J = 7.1Hz) 54.7 4.01 (t, J = 7.1) 53.7 
10 CH2 or H±C 1.99 ± 1.94 (m), 1.57 ± 1.53 (m) 39.4 2.03 (m), 1.47 (m) 39.0 
11 H±C, Me or CH2 2.06 ± 2.01 (m) 25.7 1.76 (m) 25.0 
12 Me 1.01 (d, J = 6.5) 23.4 0.97 (d, J = 6.5) 23.0 
13 Me 0.97 (d, J = 6.5) 22.2 0.91 (d, J = 6.5) 22.0 
Hz hertz, įH coupling constants (J) for H, įC coupling constants (J) for C, s singlet, d doublet, 646 
t triplet, m multiplet, q quadruplet, br broad. 647 
 648 
 649 
 650 
 651 
 652 
 653 
 654 
 655 
 656 
 657 
 658 
 659 
 660 
 661 
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FIGURE LEGENDS 662 
 663 
Fig. 1. ,QKLELWLRQUDWHRQ'$DQGVXUYLYDOWLPHGD\%RIPLFHJURXSVWUHDWHGZLWK664 
YDULRXVFRQFHQWUDWLRQRIHWK\ODFHWDWH-68.-68.DQG-68.FUXGHH[WUDFWZKHUH665 
LQGLFDWHGS 666 
 667 
Fig. 2. Blood slides taken on D4 post-infection in mice no.1 after four days daily treatment 668 
with ethyl acetate-SUK10 crude extract at particular concentration: (A) 5 µg kg-1 bw  (B) 10 669 
µg kg-1 bw (C) 50 µg kg-1 bw (D) 100 µg kg-1 bw, (E) 200 µg kg-1 bw, (F) positive control of 670 
10 mg kg-1 bw quinine hydrochloride and (G) negative control of 0.9% normal saline. All 671 
four main stages of P. berghei lifecycle were successfully captured in the infected-RBC of 672 
the mice consisted ring stage (R), trophozoite (T), schizont (S) and gametocyte (G). 673 
 674 
Fig. 3. ,QKLELWLRQUDWHRQ'$DQGVXUYLYDOWLPHGD\%RIPLFHJURXSVWUHDWHGZLWK675 
YDULRXVFRQFHQWUDWLRQRIHWK\ODFHWDWH-68.ZKHUHLQGLFDWHGS 676 
 677 
Fig. 4. Neighbour joining phylogenetic tree constructed for SUK10 isolate showed that it was 678 
felt among the same genus cluster of Streptomyces as its genomic sequences is 96 % identical 679 
with Streptomyces hygroscopicus subsp. jinggangensis. 680 
 681 
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